Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of an Innovative Rapid Diagnostic Test for Human Strongyloidiasis to Detect Specific IgG Antibody in Whole-Blood Samples.
Am J Trop Med Hyg
December 2024
Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Human strongyloidiasis is an important intestinal parasitic disease that affects public health globally and is transmitted through contact with infective larvae on contaminated soil. Immunocompromised hosts can experience hyperinfection, which can lead to fatal systemic strongyloidiasis. Here, an innovative point-of-care (POC) test kit, the strongyloidiasis immunochromatographic blood test (the NIE-SsIR whole-blood ICT) kit is described.
View Article and Find Full Text PDFThe transmission dynamics of and the impact of mass drug administration.
Philos Trans R Soc Lond B Biol Sci
January 2024
Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, Praed Street, London W2 1PG, UK.
The epidemiology of is briefly reviewed with an emphasis on cross section and longitudinal studies of infection prevalence stratified by age, performance of different diagnostic tools, mass drug administration (MDA) impact and estimates of key population parameters within the complex life cycle of the parasite that determine transmission intensity and response to control measures. The paucity of studies is highlighted, and gaps in current knowledge identified about the population biology of this very prevalent infection in tropical and sub-tropical regions around the world. A stochastic individual based stochastic model is described in part to highlight gaps in knowledge.
View Article and Find Full Text PDFNew Perspectives about Drug Candidates Targeting HTLV-1 and Related Diseases.
Pharmaceuticals (Basel)
November 2023
Tropical Medicine Center, Federal University of Para, Belem 66055-240, Brazil.
Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection syndrome or disseminated strongyloidiasis. There is currently no globally standard first-line treatment for HTLV-1 infection and its related diseases. To address this, a comprehensive review was conducted, analyzing 30 recent papers from databases PubMed, CAPES journals, and the Virtual Health Library (VHL).
View Article and Find Full Text PDFIvermectin systemic availability in adult volunteers treated with different oral pharmaceutical formulations.
Biomed Pharmacother
April 2023
Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), UNCPBA-CICPBA-CONICET, Tandil, Buenos Aires, Argentina; Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Facultad de Ciencias Veterinarias, Tandil, Buenos Aires, Argentina.
Unlabelled: Ivermectin (IVM) is currently approved as an antiparasitic agent for human use in the treatment of onchocerciasis, lymphatic filariasis, strongyloidiasis, scabies, and pediculosis. Recent findings indicate that IVM may reach other pharmacological targets, which accounts for its proven anti-inflammatory/immunomodulatory, cytostatic, and antiviral effects. However, little is known about the assessment of alternative drug formulations for human use.
View Article and Find Full Text PDFOptimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling.
Clin Transl Sci
March 2022
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.
Moxidectin is a frontrunner drug candidate in the treatment of strongyloidiasis. A dose of 8 mg is recommended to treat this indication, which shows a reasonably good efficacy and tolerability profile. Yet, owing to the unique life cycle of Strongyloides stercoralis (S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!